Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 3 offerings, 6 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-594680 | Aug 19, 2026 EDGAR ↗ | Sep 23, 2026 D/A EDGAR ↗ | 1 latest Sep 23, 2026 | $450,000 | $450,000 | Agriculture |
| 021-543271 | Apr 9, 2025 EDGAR ↗ | Apr 17, 2025 D/A EDGAR ↗ | 1 latest Apr 17, 2025 | $75,000,000 | $0 | Biotechnology |
| 021-534218 | Jan 6, 2025 EDGAR ↗ | Jan 30, 2025 D/A EDGAR ↗ | 1 latest Jan 30, 2025 | $3,970,000 | $3,970,000 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Sep 23, 2026 D/A Agriculture — $450,000 sold of $450,000 · 3 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Sep 23, 2026 · amends 0002043905-26-000001 ↗SEC file no. 021-594680 · accession 0002128191-26-000002 · filing 2 of 2 in this offering |
|---|
| Raise progress | $450,000 sold of $450,000 offered (100%) · $0 remaining · first sale Jul 23, 2026 |
|---|
| Filing timing | Date of first sale: Jul 23, 2026 · Original Form D filed: Aug 19, 2026 (27 days after first sale) · This amendment (Form D/A) filed: Sep 23, 2026 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 93 days (0.3 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Sep 23, 2026. Most recent amendment for this offering in our index: this filing, Sep 23, 2026. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 3 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
|---|
| Minimum investment accepted | $100,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in OKLAHOMA · formed 2021 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Agriculture |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Arden Anderson, Attorney in fact (Sep 23, 2026) |
|---|
| Changes vs previous filing | - total sold: $100,000 (Aug 19, 2026) → $450,000 (Sep 23, 2026)
- total offering: $3,000,000 (Aug 19, 2026) → $450,000 (Sep 23, 2026)
- remaining: $2,900,000 (Aug 19, 2026) → $0 (Sep 23, 2026)
- investors: 1 (Aug 19, 2026) → 3 (Sep 23, 2026)
- minimum investment: $1 (Aug 19, 2026) → $100,000 (Sep 23, 2026)
- industry: Biotechnology (Aug 19, 2026) → Agriculture (Sep 23, 2026)
- securities offered: Equity (Aug 19, 2026) → Debt; Option, warrant or other right to acquire (Sep 23, 2026)
- related persons no longer listed (Sep 23, 2026): Gary Holland, Tim Lozott
Compared with the D filed Aug 19, 2026 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $100,000. Typical range for similar offerings: $13,894–$100,000.
Offering size: $450,000. Typical range: $1,500,000–$10,000,000.
Investors: 3. Typical range: 1–21."Similar" = Agriculture, Rule 506(c). Based on 87 Form D filings 2021–2026 in the same industry and exemption (Agriculture, Rule 506(c); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 70, offering size 68, investors 54. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Aug 19, 2026 D Biotechnology — $100,000 sold of $3,000,000 · 1 investors EDGAR ↗
| Filing | Form D filed Aug 19, 2026SEC file no. 021-594680 · accession 0002043905-26-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $100,000 sold of $3,000,000 offered (3%) · $2,900,000 remaining · first sale Jul 23, 2026 |
|---|
| Filing timing | Date of first sale: Jul 23, 2026 · Form D filed: Aug 19, 2026 (27 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 93 days (0.3 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Sep 23, 2026 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 1 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
|---|
| Minimum investment accepted | $1 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in OKLAHOMA · formed 2021 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Arden Anderson, Attorney in fact (Aug 18, 2026) |
|---|
| Market context | Minimum investment: $1. Typical range for similar offerings: $10,000–$50,000.
Offering size: $3,000,000. Typical range: $2,000,000–$14,000,000.
Investors: 1. Typical range: 1–19."Similar" = Biotechnology, Rule 506(c). Based on 163 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(c); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 111, offering size 150, investors 123. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 17, 2025 D/A Biotechnology — $0 sold of $75,000,000 · 0 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Apr 17, 2025 · amends 0002043905-25-000003 ↗SEC file no. 021-543271 · accession 0002043905-25-000004 · filing 2 of 2 in this offering |
|---|
| Raise progress | $0 sold of $75,000,000 offered (0%) · $75,000,000 remaining |
|---|
| Filing timing | Date of first sale: Yet to occur · Original Form D filed: Apr 9, 2025 · This amendment (Form D/A) filed: Apr 17, 2025 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Apr 17, 2025. Most recent amendment for this offering in our index: this filing, Apr 17, 2025. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 0 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
|---|
| Minimum investment accepted | $50,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in OKLAHOMA · formed 2021 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) Issuer's note: No proceeds from the offering are intended to be used for payments to executive officers, directors, or promoters. |
|---|
| Signed by | Carolyn Gonzales, Attorney in Fact (Apr 16, 2025) |
|---|
| Changes vs previous filing | - proceeds to insiders: $1,295,905 (Apr 9, 2025) → $0 (Apr 17, 2025)
Compared with the D filed Apr 9, 2025 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $50,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $75,000,000. Typical range: $2,000,000–$14,000,000.
Investors: 0. Typical range: 1–19."Similar" = Biotechnology, Rule 506(c). Based on 163 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(c); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 111, offering size 150, investors 123. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 9, 2025 D Biotechnology — $0 sold of $75,000,000 · 0 investors EDGAR ↗
| Filing | Form D filed Apr 9, 2025SEC file no. 021-543271 · accession 0002043905-25-000003 · filing 1 of 2 in this offering |
|---|
| Raise progress | $0 sold of $75,000,000 offered (0%) · $75,000,000 remaining |
|---|
| Filing timing | Date of first sale: Yet to occur · Form D filed: Apr 9, 2025 Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Apr 17, 2025 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 0 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
|---|
| Minimum investment accepted | $50,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in OKLAHOMA · formed 2021 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $1,295,905 (est.) Issuer's note: Travis Dahm (CEO) - $545,000 total compensation; Gary Holland (CIO) - $545,000 total compensation ; Time Lozott (CFO / COO) - 205,905 total compensation |
|---|
| Signed by | Carolyn Gonzales, Attorney in Fact (Apr 9, 2025) |
|---|
| Market context | Minimum investment: $50,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $75,000,000. Typical range: $2,000,000–$14,000,000.
Investors: 0. Typical range: 1–19."Similar" = Biotechnology, Rule 506(c). Based on 163 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(c); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 111, offering size 150, investors 123. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jan 30, 2025 D/A Biotechnology — $3,970,000 sold of $3,970,000 · 31 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Jan 30, 2025 · amends 0002043905-25-000001 ↗SEC file no. 021-534218 · accession 0002043905-25-000002 · filing 2 of 2 in this offering |
|---|
| Raise progress | $3,970,000 sold of $3,970,000 offered (100%) · $0 remaining · first sale Mar 1, 2024 |
|---|
| Filing timing | Date of first sale: Mar 1, 2024 · Original Form D filed: Jan 6, 2025 (311 days after first sale) · This amendment (Form D/A) filed: Jan 30, 2025 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 967 days (2.6 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jan 30, 2025. Most recent amendment for this offering in our index: this filing, Jan 30, 2025. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 31 total · includes 4 non-accredited investors |
|---|
| Exemption claimed | Rule 504 — smaller offerings (currently up to $10 million in 12 months) |
|---|
| Minimum investment accepted | $5,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in OKLAHOMA · formed 2021 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Carolyn Gonzales, Attorney in Fact (Jan 30, 2025) |
|---|
| Changes vs previous filing | - related persons added (Jan 30, 2025): Tim Lozott
- related persons no longer listed (Jan 30, 2025): Tim Lozot
Compared with the D filed Jan 6, 2025 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not available for this filing — it claims Rule 504 — smaller offerings (currently up to $10 million in 12 months); ranges are computed only for offerings claiming Rule 506(b) or 506(c). |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jan 6, 2025 D Biotechnology — $3,970,000 sold of $3,970,000 · 31 investors EDGAR ↗
| Filing | Form D filed Jan 6, 2025SEC file no. 021-534218 · accession 0002043905-25-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $3,970,000 sold of $3,970,000 offered (100%) · $0 remaining · first sale Mar 1, 2024 |
|---|
| Filing timing | Date of first sale: Mar 1, 2024 · Form D filed: Jan 6, 2025 (311 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 967 days (2.6 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jan 30, 2025 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 31 total · includes 4 non-accredited investors |
|---|
| Exemption claimed | Rule 504 — smaller offerings (currently up to $10 million in 12 months) |
|---|
| Minimum investment accepted | $5,000 |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in OKLAHOMA · formed 2021 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Carolyn Gonzales, Attorney in Fact (Jan 3, 2025) |
|---|
| Market context | Not available for this filing — it claims Rule 504 — smaller offerings (currently up to $10 million in 12 months); ranges are computed only for offerings claiming Rule 506(b) or 506(c). |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Amendment history — 3 amendments on this page, each compared with the filing before it in the same offering
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|
| Sep 23, 2026 EDGAR ↗ | 021-594680 | Aug 19, 2026 D | total sold: $100,000 (Aug 19, 2026) → $450,000 (Sep 23, 2026) · total offering: $3,000,000 (Aug 19, 2026) → $450,000 (Sep 23, 2026) · remaining: $2,900,000 (Aug 19, 2026) → $0 (Sep 23, 2026) · and 5 more (open the filing above) |
| Apr 17, 2025 EDGAR ↗ | 021-543271 | Apr 9, 2025 D | proceeds to insiders: $1,295,905 (Apr 9, 2025) → $0 (Apr 17, 2025) |
| Jan 30, 2025 EDGAR ↗ | 021-534218 | Jan 6, 2025 D | related persons added (Jan 30, 2025): Tim Lozott · related persons no longer listed (Jan 30, 2025): Tim Lozot |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 1 new offering in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Sep 23, 2026. Industry as reported, by offering: Previous offerings: Biotechnology (2025). Latest offering: Agriculture (Aug 19, 2026).
Key people 4
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| TD Travis Dahm | Executive Officer, Director | OK | Jan 6, 2025 → Sep 23, 2026 on 6 of 6 filings listed on the latest filing | — |
| GH Gary Holland | Executive Officer | OK | Jan 6, 2025 → Aug 19, 2026 on 5 of 6 filings not listed on the latest filing (Sep 23, 2026) | — |
| TL Tim Lozott | Executive Officer | OK | Jan 30, 2025 → Aug 19, 2026 on 4 of 6 filings not listed on the latest filing (Sep 23, 2026) | — |
| TL Tim Lozot | Executive Officer | OK | Jan 6, 2025 on 1 of 6 filings not listed on the latest filing (Sep 23, 2026) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
No other issuers in our index list the same related persons. Searched: related-person listings on every Form D filing in our index, 2008 → Oct 22, 2026.
Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.
Other offering types (Regulation A and Regulation Crowdfunding)
2 Regulation A filings — tap to see each filing
| Source | Filed | Form | Issuer | Amount offered (as reported) | Amount sold (as reported) | Matched on |
|---|
| EDGAR ↗ | Mar 31, 2025 File 024-12557 | Regulation A offering statement — amendment (Form 1-A/A) Amendment filed | Endless Corporation Tulsa, OK | $75,000,000 · Tier 2 | Not reported on this form | same CIK (SEC registrant number) as the Form D issuer · 100% |
| EDGAR ↗ | Jan 24, 2025 File 024-12557 | Regulation A offering statement (Form 1-A) Offering statement filed | Endless Corporation Tulsa, OK | $75,000,000 · Tier 2 | Not reported on this form | same CIK (SEC registrant number) as the Form D issuer · 100% |
Amounts are as reported by the issuer on the form; Regulation Crowdfunding forms report a target and maximum, not sales. Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Adviser registration (Form ADV)
ENDLESS LLP — Exempt reporting adviser · SEC registration status as reported: “ERA - Active” since Mar 29, 2012 · SEC file 802-75324 · Main office: LEEDS · IAPD record ↗ · Form ADV filing (PDF) ↗
Regulatory assets under management: Not reported — exempt reporting advisers do not complete Form ADV Item 5.
Websites listed on Form ADV (Item 1.I): www.endlessllp.com ↗
Item 11 disclosure questions as answered on Form ADV filed May 27, 2026: 0 of 24 answered “Yes”
- No — Form ADV Item 11 asks: “Do any of the events below involve you or any of your supervised persons?”
- No — Form ADV Item 11A(1) asks: “A. In the past ten years, have you or any advisory affiliate: (1) been convicted of or pled guilty or nolo contendere ("no contest") in a domestic, foreign, or military court to any felony?”
- No — Form ADV Item 11A(2) asks: “A. (2) been charged with any felony?”
- No — Form ADV Item 11B(1) asks: “B. In the past ten years, have you or any advisory affiliate: (1) been convicted of or pled guilty or nolo contendere ("no contest") in a domestic, foreign, or military court to a misdemeanor involving: investments or an investment-related business, or any fraud, false statements, or omissions, wrongful taking of property, bribery, perjury, forgery, counterfeiting, extortion, or a conspiracy to commit any of these offenses?”
- No — Form ADV Item 11B(2) asks: “B. (2) been charged with a misdemeanor listed in Item 11.B(1)?”
- No — Form ADV Item 11C(1) asks: “C. Has the SEC or the Commodity Futures Trading Commission (CFTC) ever: (1) found you or any advisory affiliate to have made a false statement or omission?”
- No — Form ADV Item 11C(2) asks: “C. (2) found you or any advisory affiliate to have been involved in a violation of SEC or CFTC regulations or statutes?”
- No — Form ADV Item 11C(3) asks: “C. (3) found you or any advisory affiliate to have been a cause of an investment-related business having its authorization to do business denied, suspended, revoked, or restricted?”
- No — Form ADV Item 11C(4) asks: “C. (4) entered an order against you or any advisory affiliate in connection with investment-related activity?”
- No — Form ADV Item 11C(5) asks: “C. (5) imposed a civil money penalty on you or any advisory affiliate, or ordered you or any advisory affiliate to cease and desist from any activity?”
- No — Form ADV Item 11D(1) asks: “D. Has any other federal regulatory agency, any state regulatory agency, or any foreign financial regulatory authority: (1) ever found you or any advisory affiliate to have made a false statement or omission, or been dishonest, unfair, or unethical?”
- No — Form ADV Item 11D(2) asks: “D. (2) ever found you or any advisory affiliate to have been involved in a violation of investment-related regulations or statutes?”
- No — Form ADV Item 11D(3) asks: “D. (3) ever found you or any advisory affiliate to have been a cause of an investment-related business having its authorization to do business denied, suspended, revoked, or restricted?”
- No — Form ADV Item 11D(4) asks: “D. (4) in the past ten years, entered an order against you or any advisory affiliate in connection with an investment-related activity?”
- No — Form ADV Item 11D(5) asks: “D. (5) ever denied, suspended, or revoked your or any advisory affiliate's registration or license, or otherwise prevented you or any advisory affiliate, by order, from associating with an investment-related business or restricted your or any advisory affiliate's activity?”
- No — Form ADV Item 11E(1) asks: “E. Has any self-regulatory organization or commodities exchange ever: (1) found you or any advisory affiliate to have made a false statement or omission?”
- No — Form ADV Item 11E(2) asks: “E. (2) found you or any advisory affiliate to have been involved in a violation of its rules (other than a violation designated as a "minor rule violation" under a plan approved by the SEC)?”
- No — Form ADV Item 11E(3) asks: “E. (3) found you or any advisory affiliate to have been the cause of an investment-related business having its authorization to do business denied, suspended, revoked, or restricted?”
- No — Form ADV Item 11E(4) asks: “E. (4) disciplined you or any advisory affiliate by expelling or suspending you or the advisory affiliate from membership, barring or suspending you or the advisory affiliate from association with other members, or otherwise restricting your or the advisory affiliate's activities?”
- No — Form ADV Item 11F asks: “F. Has an authorization to act as an attorney, accountant, or federal contractor granted to you or any advisory affiliate ever been revoked or suspended?”
- No — Form ADV Item 11G asks: “G. Are you or any advisory affiliate now the subject of any regulatory proceeding that could result in a "yes" answer to any part of Item 11.C., 11.D., or 11.E.?”
- No — Form ADV Item 11H(1)(a) asks: “H. (1) Has any domestic or foreign court: (a) in the past ten years, enjoined you or any advisory affiliate in connection with any investment-related activity?”
- No — Form ADV Item 11H(1)(b) asks: “H. (1)(b) ever found that you or any advisory affiliate were involved in a violation of investment-related statutes or regulations?”
- No — Form ADV Item 11H(1)(c) asks: “H. (1)(c) ever dismissed, pursuant to a settlement agreement, an investment-related civil action brought against you or any advisory affiliate by a state or foreign financial regulatory authority?”
- No — Form ADV Item 11H(2) asks: “H. (2) Are you or any advisory affiliate now the subject of any civil proceeding that could result in a "yes" answer to any part of Item 11.H(1)?”
Answers as filed by the adviser on Form ADV Part 1A, Item 11; question text quoted from the form. Details of each “Yes” are in the Disclosure Reporting Pages of the Form ADV (PDF) ↗.
Matched on issuer name = adviser name, different legal form as filed (LP vs Corp), no state to compare · Form ADV data: SEC Investment Adviser Information Report (exempt reporting advisers), file dated 2026-10-02, loaded Oct 23, 2026, 8:39 PM ET · IAPD record last checked Oct 23, 2026, 8:36 PM ET
Meta advertising
No Meta Pixel ids or Facebook / Instagram page links on file for Endless Corp as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.
Public profiles
Public profiles official links and public statements, each with its source and date
No website or social profile named in Endless Corp's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #7,333 of 374,652 in line (14 issuers searched so far).
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for OK yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.